Cefoxitin sodium
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-03864 |
| CAS | 33564-30-6 |
| Molecular Weight | 449.43 |
| Molecular Formula | C16H16N3NaO7S2 |
| Purity | ≥95% |
Online Inquiry
Capabilities & Facilities
Fermentation Lab
4 R&D and scale-up labs
2 Preparative purification labs
Fermentation Plant
Semi pilot, pilot and industrial plant 4 Manufacturing sites 7 Production lines at pilot scale 100+ Reactors of 30-4000 L; 170+ reactors of 20 KL-30 KL; 24+ reactors of >100 KL 2 Hydrogenation reactors (200 L, 4Mpa and 1000L, 4Mpa)
Product Description
Cefoxitin is derived from cephamycin C, a semi-synthetic, broad-spectrum cepha antibiotic often grouped with the second-generation cephalosporins.
- Specification
- Properties
- Reference Reading
- Price Product List
| Related CAS | 35607-66-0 (free base) |
| Synonyms | MK-306; MK 306; MK306; (6R,7S)-3-[[(Aminocarbonyl)oxy]methyl]-7-methoxy-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid Sodium Salt |
| Shelf Life | As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly |
| Storage | Store at -20°C |
| IUPAC Name | sodium;(6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Canonical SMILES | COC1(C2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)[O-])NC(=O)CC3=CC=CS3.[Na+] |
| InChI | InChI=1S/C16H17N3O7S2.Na/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19;/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22);/q;+1/p-1/t14-,16+;/m1./s1 |
| InChI Key | GNWUOVJNSFPWDD-XMZRARIVSA-M |
| Source | Semi-synthetic |
| Appearance | White Solid |
| Application | Antibacterial |
| Antibiotic Activity Spectrum | bacteria |
| Boiling Point | 843.4°C at 760 mmHg |
| Melting Point | >160°C |
| Solubility | Soluble in DMSO |
1.Evaluation of Genotypic and Phenotypic Methods for Detection of Methicillin Resistant Staphylococcus aureus in a Tertiary Care Hospital of Eastern Odisha.
Panda RK1, Mahapatra A2, Mallick B3, Chayani N4. J Clin Diagn Res. 2016 Feb;10(2):DC19-21. doi: 10.7860/JCDR/2016/17476.7278. Epub 2016 Feb 1.
INTRODUCTION: Methicillin resistant Staphylococcus aureus has emerged as an important pathogen in nosocomial and community acquired infections. Accurate and rapid identification of MRSA in clinical specimens is essential for timely decision of effective antimicrobial chemotherapy.
2.Analysis of drug resistance in 1,861 strains of Acinetobacter baumannii.
Jin H1, Qiu F2, Ji HJ1, Lu Q1. Biomed Rep. 2016 Apr;4(4):463-466. Epub 2016 Feb 15.
Acinetobacter baumannii is an emerging human pathogen that causes hospital-acquired infections. The trend in increased antimicrobial resistance limits the choice of effective antimicrobial agents. The present study reports the resistance to Acinetobacter baumannii and analyzes the associations between antibiotic use and resistance rates at a general hospital between 2010 and 2014. A total of 1,861 isolates were obtained from clinical cultures, accounting for 10.33% of all detected bacteria (1,861/18,016). The strains were mainly from respiratory samples (1,628 isolates, 87.5%) and the intensive care unit (696 isolates, 37.4%). The resistance rates of Acinetobacter baumannii to the majority of antibiotics were >50%, particularly the resistance rate to cefoperazone/sulbactam increased from 47.37 in 2011 to 89.25% in 2014. However, the rates of imipenem and cilastatin sodium decreased from 81.03 to 69.44% due to the antibiotic policy. There were Pearson significant associations between the use of three antibiotics and resistance in Acinetobacter baumannii to this drug, piperacillin/tazobactam (r=0.
3.Prevalence of antibiotic resistant Staphylococcus aureus from raw milk samples collected from the local vendors in the region of Tirupathi, India.
Sudhanthiramani S1, Swetha CS1, Bharathy S1. Vet World. 2015 Apr;8(4):478-81. doi: 10.14202/vetworld.2015.478-481. Epub 2015 Apr 12.
AIM: The study was carried out with the aim to identify the suitability of the milk for consumer use with special reference to Staphylococcus aureus from milk samples collected from various local vendors and determine the antibiotic susceptibility pattern of those positive isolates.
4.THE FREQUENCY OF COMMUNITY-ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (CA-MRSA) AMONG SAMPLES IN INSTITUTE FOR PUBLIC HEALTH IN CANTON SARAJEVO.
Bektas S1, Obradovic A1, Aljicevic M2, Numanovic F3, Hodzic D1, Sporisevic L4. Mater Sociomed. 2016 Feb;28(1):61-5. doi: 10.5455/msm.2016.28.61-65. Epub 2016 Jan 30.
BACKGROUND: The increase in the incidence of methicillin-resistant Staphylococcus aureus (MRSA) infections lacking risk factors for exposure to the health care system has been associated with the recognition of new MRSA clones known as community-associated MRSA (CA-MRSA). These strains have been distinguished from health care-associated MRSA (HA-MRSA) strains by epidemiological, molecular and genetic means as well as by antibiotic susceptibility profile, tissue tropism and virulence traits.
| BBF-05853 | Palbociclib | Inquiry |
| BBF-03794 | Geneticin sulfate | Inquiry |
| BBF-03904 | Nosiheptide | Inquiry |
| BBF-04621 | Artemisinin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-04624 | Sulbactam Sodium | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
